Matthew S. Davids

Harvard University — United States

Medicine · Health Sciences

60h-index17.6kcitations639works3.22yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Chronic Lymphocytic Leukemia Research(475), Lymphoma Diagnosis and Treatment(225), Chronic Myeloid Leukemia Treatments(93), Immunodeficiency and Autoimmune Disorders(78), Acute Lymphoblastic Leukemia research(69)

Publications638 total

Efficacy of Pirtobrutinib Monotherapy in Treatment-Naïve Chronic Lymphocytic Leukemia: A Bayesian Network Meta-Analysis of Randomized Controlled Trials
Cancers·2026Open Access
Targeting β-catenin degradation with GSK3β inhibitors induces cell death in acute lymphoblastic leukemia
Nature Cancer·2026Open Access
First-line treatment for CLL in the era of targeted therapy
Blood Cancer Journal·2026· 1 citedOpen Access
CD47 blockade-driven necroptosis complements BCL-2 inhibition-driven apoptosis in lymphoid malignancies
Journal of Hematology & Oncology·2026Open Access
CD47 blockade-driven necroptosis complements BCL-2 inhibition-driven apoptosis in lymphoid malignancies
Figshare·2026Open Access
P-2132. A population-based assessment of infectious complications in patients with chronic lymphocytic leukemia (CLL) exposed to ibrutinib
Open Forum Infectious Diseases·2026Open Access
Additional file 1 of CD47 blockade-driven necroptosis complements BCL-2 inhibition-driven apoptosis in lymphoid malignancies
Figshare·2026Open Access
Additional file 1 of CD47 blockade-driven necroptosis complements BCL-2 inhibition-driven apoptosis in lymphoid malignancies
Figshare·2026Open Access
CD47 blockade-driven necroptosis complements BCL-2 inhibition-driven apoptosis in lymphoid malignancies
Figshare·2026Open Access
Acalabrutinib to assail CLL in the frail
Blood·2025
BRUIN 313 and 314 Trials Open the Door for Noncovalent Bruton Tyrosine Kinase Inhibition as Initial Therapy for Chronic Lymphocytic Leukemia
Journal of Clinical Oncology·2025
Integrating single-cell biophysical and transcriptomic features to resolve functional heterogeneity in mantle cell lymphoma
Science Advances·2025Open Access
Supplementary Figures S1-S7 from Novel BCL-2 Inhibitor Lisaftoclax in Relapsed or Refractory Chronic Lymphocytic Leukemia and Other Hematologic Malignancies: First-in-Human Open-Label Trial
2025Open Access
Table S2 from Novel BCL-2 Inhibitor Lisaftoclax in Relapsed or Refractory Chronic Lymphocytic Leukemia and Other Hematologic Malignancies: First-in-Human Open-Label Trial
2025Open Access
Table S1 from Novel BCL-2 Inhibitor Lisaftoclax in Relapsed or Refractory Chronic Lymphocytic Leukemia and Other Hematologic Malignancies: First-in-Human Open-Label Trial
2025Open Access
Supplementary Tables from <i>In Vivo</i> Modeling of CLL Transformation to Richter Syndrome Reveals Convergent Evolutionary Paths and Therapeutic Vulnerabilities
2025Open Access
Supplementary Figures from <i>In Vivo</i> Modeling of CLL Transformation to Richter Syndrome Reveals Convergent Evolutionary Paths and Therapeutic Vulnerabilities
2025Open Access
Pirtobrutinib outcomes in second-line (2L) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) after first-line (1L) cBTKi therapy: A pooled analysis from the BRUIN LOXO-BTK-18001 and BRUIN CLL-321 studies
Blood·2025
Rituximab and epcoritamab as first-line therapy for patients with high-tumor burden follicular lymphoma: Results of a multicenter phase II trial
Blood·2025
Nodal progression in CLL: Real-world predictors of richter transformation and identification of a distinct high-risk NP-CLL subgroup
Blood·2025Open Access
page 1 of 32Next →

Frequent Co-authors

Jennifer R. Brown(23), William G. Wierda(12), Anthony Letai(10), Andrew W. Roberts(9), John F. Seymour(9), Philippe Armand(9), David C. Fisher(9), Caron A. Jacobson(9), Thomas J. Kipps(8), Rod Humerickhouse(7), Haesook T. Kim(7), Catherine J. Wu(7), Mary Ann Anderson(6), Maria Verdugo(6), Donna Neuberg(6), Arnold S. Freedman(6), Eric D. Jacobsen(6), Ann S. LaCasce(6), John M. Pagel(5), John F. Gerecitano(5)